Editorially Independent content supported with advertising by Novartis and Alcon.
Arshad M. Khanani, MD, MA
Show Description +
Arshad M. Khanani, MD, MA, shares the case of a patient with long-standing wet AMD who had experienced complications of tachyphylaxis related to available anti-VEGF agents around the time that brolucizumab (Beovu, Novartis) was approved for marketing in the United States. How did this patient, who had a history of intraocular inflammation, fare on brolucizumab therapy?
Posted: 8/05/2021
Arshad M. Khanani, MD, MA
Arshad M. Khanani, MD, MA, shares the case of a patient with long-standing wet AMD who had experienced complications of tachyphylaxis related to available anti-VEGF agents around the time that brolucizumab (Beovu, Novartis) was approved for marketing in the United States. How did this patient, who had a history of intraocular inflammation, fare on brolucizumab therapy?
Posted: 8/05/2021
New Retina Radio
All video episodes of this series are also available as podcast episodes on New Retina Radio.
Please log in to leave a comment.